Lipocine Statistics
Total Valuation
Lipocine has a market cap or net worth of $17.15 million. The enterprise value is -$2.22 million.
Important Dates
The next estimated earnings date is Thursday, August 7, 2025, before market open.
| Earnings Date | Aug 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Lipocine has 5.35 million shares outstanding. The number of shares has increased by 1.08% in one year.
| Current Share Class | 5.35M |
| Shares Outstanding | 5.35M |
| Shares Change (YoY) | +1.08% |
| Shares Change (QoQ) | -5.88% |
| Owned by Insiders (%) | 2.95% |
| Owned by Institutions (%) | 9.73% |
| Float | 5.19M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4.66 |
| Forward PS | 15.15 |
| PB Ratio | 0.89 |
| P/TBV Ratio | 0.89 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 15.64, with a Debt / Equity ratio of 0.02.
| Current Ratio | 15.64 |
| Quick Ratio | 15.31 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -24.89% and return on invested capital (ROIC) is -18.44%.
| Return on Equity (ROE) | -24.89% |
| Return on Assets (ROA) | -17.60% |
| Return on Invested Capital (ROIC) | -18.44% |
| Return on Capital Employed (ROCE) | -33.69% |
| Revenue Per Employee | $229,677 |
| Profits Per Employee | -$335,634 |
| Employee Count | 16 |
| Asset Turnover | 0.16 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Lipocine has paid $681 in taxes.
| Income Tax | 681 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -69.69% in the last 52 weeks. The beta is 1.33, so Lipocine's price volatility has been higher than the market average.
| Beta (5Y) | 1.33 |
| 52-Week Price Change | -69.69% |
| 50-Day Moving Average | 3.26 |
| 200-Day Moving Average | 4.13 |
| Relative Strength Index (RSI) | 47.19 |
| Average Volume (20 Days) | 62,218 |
Short Selling Information
The latest short interest is 96,289, so 1.80% of the outstanding shares have been sold short.
| Short Interest | 96,289 |
| Short Previous Month | 84,973 |
| Short % of Shares Out | 1.80% |
| Short % of Float | 1.85% |
| Short Ratio (days to cover) | 1.52 |
Income Statement
In the last 12 months, Lipocine had revenue of $3.67 million and -$5.37 million in losses. Loss per share was -$1.02.
| Revenue | 3.67M |
| Gross Profit | 3.67M |
| Operating Income | -6.47M |
| Pretax Income | -8.49M |
| Net Income | -5.37M |
| EBITDA | -6.42M |
| EBIT | -6.47M |
| Loss Per Share | -$1.02 |
Full Income StatementBalance Sheet
The company has $19.72 million in cash and $345,839 in debt, giving a net cash position of $19.37 million or $3.62 per share.
| Cash & Cash Equivalents | 19.72M |
| Total Debt | 345,839 |
| Net Cash | 19.37M |
| Net Cash Per Share | $3.62 |
| Equity (Book Value) | 19.20M |
| Book Value Per Share | 3.59 |
| Working Capital | 19.03M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$5.60 million and capital expenditures -$90,086, giving a free cash flow of -$5.69 million.
| Operating Cash Flow | -5.60M |
| Capital Expenditures | -90,086 |
| Free Cash Flow | -5.69M |
| FCF Per Share | -$1.06 |
Full Cash Flow StatementMargins
Gross margin is 100.00%, with operating and profit margins of -176.00% and -146.13%.
| Gross Margin | 100.00% |
| Operating Margin | -176.00% |
| Pretax Margin | -146.11% |
| Profit Margin | -146.13% |
| EBITDA Margin | -174.69% |
| EBIT Margin | -176.00% |
| FCF Margin | n/a |
Dividends & Yields
Lipocine does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.08% |
| Shareholder Yield | -1.08% |
| Earnings Yield | -31.32% |
| FCF Yield | -33.17% |
Analyst Forecast
The average price target for Lipocine is $9.00, which is 177.78% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $9.00 |
| Price Target Difference | 177.78% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | 36.22% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on May 12, 2023. It was a reverse split with a ratio of 0.0588235:1.
| Last Split Date | May 12, 2023 |
| Split Type | Reverse |
| Split Ratio | 0.0588235:1 |
Scores
Lipocine has an Altman Z-Score of -1 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1 |
| Piotroski F-Score | 1 |